AI Earnings Predictions for Travere Therapeutics Inc. (TVTX)

EX-99.1

2 a2026q3_8-kxex991.htm

EX-99.1

Document

Exhibit 99.1

Contact:

Investors:Media:

888-969-7879888-969-7879

IR@travere.commediarelations@travere.com

Travere Therapeutics Reports Third Quarter 2026 Financial Results

U.S. net product sales of FILSPARI® totaled $200 million, representing 120% growth year-over-year; 1,932 new PSFs received during the quarter

Phase 3 HARMONY Study of pegtibatinase enrollment progressing; topline results on track for the second half of 2027

Civorebrutinib U.S. IND submission planned by year-end, supporting development across multiple immune-mediated kidney diseases

SAN DIEGO, November 2, 2026 – Travere Therapeutics, Inc. (Nasdaq: TVTX) today reported its third quarter 2026 financial results and provided a corporate update.

“Strong execution across our business drove another quarter of significant growth, with FILSPARI net product sales of $200 million for the quarter as we continued to expand our reach in IgAN and FSGS,” said Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics. “We remain early in reaching the more than 100,000 addressable patients across these conditions, reinforcing our confidence in FILSPARI’s substantial long-term opportunity. Alongside this commercial progress, we are advancing pegtibatinase toward pivotal Phase 3 results in the second half of next year and progressing civorebrutinib toward late-stage clinical development. As I prepare to transition leadership to Bradley Campbell in December, I have never been more confident in Travere’s future, supported by an exceptional team, an expanding pipeline and a shared commitment to delivering hope to patients.”

Financial Results for the Quarter Ended September 30, 2026

U.S. net product sales for the third quarter of 2026 were $220.2 million, compared to $113.2 million for the same period in 2025. U.S. net product sales for the nine months ended September 30, 2026, were $506.0 million, compared to $283.9 million for the same period in 2025.

•U.S. net product sales of FILSPARI totaled $200.2 million in the third quarter of 2026, representing 120% growth year-over-year. U.S. net product sales of FILSPARI for the nine months ended September 30, 2026, were $446.4 million, representing 104% growth year-over-year.

•Patient demand across IgAN and FSGS resulted in 1932 new patient start forms (PSFs) received during the third quarter of 2026, reflecting FILSPARI’s continued foundational role in IgAN and encouraging early launch momentum in FSGS.

Research and development (R&D) expenses for the third quarter of 2026 were $70.3 million, compared to $51.9 million for the same period in 2025. For the nine months ended September 30, 2026, R&D expenses were $187.7 million, compared to $148.1 million for the same period in 2025. The increase is primarily attributable to advancement of the Phase 3 HARMONY Study and manufacturing of pegtibatinase for classical homocystinuria (HCU).

•On a non-GAAP adjusted basis, R&D expenses were $63.2 million for the third quarter of 2026 and $168.1 million for the nine months ended September 30, 2026, compared to $47.8 million and $135.3 million for the same periods in 2025, respectively.

Selling, general, and administrative (SG&A) expenses for the third quarter of 2026 were $98.4 million, compared to $71.0 million for the same period in 2025. For the nine months ended September 30, 2026, SG&A expenses were $274.8 million, compared to $194.0 million for the same period in 2025. The difference is primarily attributable to commercial investments supporting the recent launch of FILSPARI in FSGS, as well as ongoing commercialization efforts in IgAN.

•On a non-GAAP adjusted basis, SG&A expenses were $81.7 million for the third quarter of 2026 and $231.8 million for the nine months ended September 30, 2026, compared to $63.5 million and $172.3 million for the same periods in 2025, respectively.

In the third quarter, the Company recognized a $113.1 million IPR&D expense as a result of the closing of its exclusive licensing and collaboration agreement with Everest Medicines for civorebrutinib.

Total other income, net for the third quarter of 2026 was $1.2 million, compared to $0.8 million for the same period in 2025. Total other expense, net for the nine months ended September 30, 2026, was $37.6 million, compared to total other income, net of $2.2 million for the same period in 2025.

Net loss for the third quarter of 2026 was $52.3 million, or $0.55 per basic share, compared to net income of $25.7 million, or $0.29 per basic share for the same period in 2025. For the nine months ended September 30, 2026, net loss was $124.2 million, compared to $28.3 million for the same period in 2025.

•On a non-GAAP adjusted basis, net loss for the third quarter of 2026 was $29.6 million, or $0.31 per basic share, compared to a net income of $52.8 million, or $0.59 per basic share for the same period in 2025. For the nine months ended September 30, 2026, non-GAAP

SEC.gov | Request Rate Threshold Exceeded

U.S. Securities and Exchange Commission

You’ve Exceeded the SEC’s Traffic Limit

Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.

Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.

The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.

For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.

For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.

Reference ID: 0.c706d217.1785932102.bf07fe96

More Information

Internet Security Policy

By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.

Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).

To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.

If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.

Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.

Note: We do not offer technical support for developing or debugging scripted downloading processes.

SEC.gov | Request Rate Threshold Exceeded

U.S. Securities and Exchange Commission

You’ve Exceeded the SEC’s Traffic Limit

Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.

Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.

The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.

For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.

For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.

Reference ID: 0.ce06d217.1784467178.b603b45c

More Information

Internet Security Policy

By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.

Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).

To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.

If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.

Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.

Note: We do not offer technical support for developing or debugging scripted downloading processes.